Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BGF MDI HFO vs HFA in Healthy Volunteers
NCT05569421Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EPI-EE, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoints: Area Under Plasma Concentration-time Curve From Zero to Infinity, Area Under the Plasma Concentration-curve From Zero to the Last Quantifiable Concentration and 1 more. Started Oct 2022; status: completed.
02
Drugs
EPI-EEglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05569421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569421.